Author

L. A. Arnold

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Approach:biophysical modeling· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

A. Jones· 1 shared A. Sharon· 1 shared B. C. Hofeld· 1 shared D. M. Jensen· 1 shared D. Ojha· 1 shared D. T. Linehan· 1 shared D. Z. Trykall· 1 shared F. C. Peterson· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Jones

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A novel Fis1 inhibiting peptide reverses diabetic endothelial dysfunction in human resistance arteries

K. A. Nolden, M. Kakarla, J. M. Egner, J. Wang, M. C. Harwig, V. K. Puppala, B. C. Hofeld, L. A. Arnold, D. Z. Trykall, F. C. Peterson, M. L. Roberts, D. M. Jensen, R. B. Hill, M. E. Widlansky

This study shows that inhibiting Fis1 improves endothelial function in diabetic vessels by enhancing NO availability and reducing mitochondrial ROS.

bioRxiv · Nov 16, 2020 · PreprintPhysiology

Targeting Vitamin-D receptor (VDR) by a small molecule antagonist MeTC7 inhibits PD-L1 but controls THMYCN neuroblastoma growth PD-L1 independently

R. K. Singh, K. Kim, R. B. Rowswell-Turner, J. N. Hansen, N. Khazan, A. Jones, U. Sivagnanalingam, Y. Teramoto, T. Goto, Y. Jian, N. Battaglia, T. Conley, V. Hovanesian, N. Yano, R. Pandita, , R. Moore

This study shows that MeTC7, a VDR antagonist, reduces PD-L1 expression in cancer cells and inhibits neuroblastoma growth independently of PD-L1.

bioRxiv · Aug 16, 2020 · PreprintCancer Biology